Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2018

01-08-2018 | Original Article – Cancer Research

Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells

Authors: Yi-Fan Li, Hou-Ting Zhang, Lin Xin

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2018

Login to get access

Abstract

Background

Gastric cancer (GC) is the second most common leading cause of cancer-related death. Cancer stem cell (CSC) with the mark of CD44 played an important role in GC. rMETase was wildly exploited as chemotherapeutic option for GC. Polymers synthetic nanoparticle drug delivery systems have been commonly used for cancer therapy. With the decorating of Hyaluronic acid (HA), a receptor of CD44, nanoparticles exhibit with good biocompatibility and aqueous solubility.

Methods

The characteristic of nanoparticles (NPs) was analyzed by TEM and DLS. The viability and proliferation of GC cells were examined by MTT assays. The levels of CD44, Cyt C, and c-caspase 3 were examined by Western blot. The level of ROS was measured by DCFH-DA assays. The morphology of tissues was detected using hematoxylin–eosin (H&E) stain. Nude mice xenograft models were used to evaluate the effect of HA-PAMAM-Au-METase on GC.

Results

The transfection of rMETase carried by HA-G5 PAMAM-Au visibly inhibited the proliferation and tumorsphere formation of GC cells through obviously enhancing METase activity. Elevation of METase activity suppressed the proliferation of CD44(+) GC cells through down-regulating MET in cellular supernatant that resulted in the increase of Cyc C and ROS levels. The number of CD44(+) GC cells in nude mice injected with G5 PAMAM-Au-METase decorated by HA was markly declined resulting in the inhibition of tumor growth.

Conclusion

HA-G5 PAMAM-Au-METase significantly suppressed tumor growth of GC by targeted damaging the mitochondrial function of CD44(+) gastric CSCs.
Appendix
Available only for authorised users
Literature
go back to reference Alison MR, Lin WR, Lim SML, Nicholson LJ (2012) Cancer stem cells: in the line of fire. Cancer Treat Rev 38:589–598CrossRefPubMed Alison MR, Lin WR, Lim SML, Nicholson LJ (2012) Cancer stem cells: in the line of fire. Cancer Treat Rev 38:589–598CrossRefPubMed
go back to reference Baker JR Jr (2009) Dendrimer-based nanoparticles for cancer therapy, Hematol Am Soc Hematol Educ Program, 708–719 Baker JR Jr (2009) Dendrimer-based nanoparticles for cancer therapy, Hematol Am Soc Hematol Educ Program, 708–719
go back to reference Bölke E, Peiper M, Budach W (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRef Bölke E, Peiper M, Budach W (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRef
go back to reference Chen J, Cao X, Guo R, Shen M, Peng C, Xiao T, Shi X (2012) A highly effective polymerase chain reaction enhancer based on dendrimer-entrapped gold nanoparticles. Analyst 137:223CrossRefPubMed Chen J, Cao X, Guo R, Shen M, Peng C, Xiao T, Shi X (2012) A highly effective polymerase chain reaction enhancer based on dendrimer-entrapped gold nanoparticles. Analyst 137:223CrossRefPubMed
go back to reference de Andrade NP, Rodrigues MF, Rodini CO, Nunes FD (2016) Cancer stem cell, cytokeratins and epithelial to mesenchymal transition markers expression in oral squamous cell carcinoma derived from ortothopic xenoimplantation of CD44(high) cells, Pathology Research & Practice, 213:235–244 de Andrade NP, Rodrigues MF, Rodini CO, Nunes FD (2016) Cancer stem cell, cytokeratins and epithelial to mesenchymal transition markers expression in oral squamous cell carcinoma derived from ortothopic xenoimplantation of CD44(high) cells, Pathology Research & Practice, 213:235–244
go back to reference Deng J, Li N, Mai K, Yang C, Yan L, Zhang LM (2011) Star-shaped polymers consisting of a β-cyclodextrin core and poly(amidoamine) dendron arms: binding and release studies with methotrexate and siRNA. J Mater Chem 21:5273–5281CrossRef Deng J, Li N, Mai K, Yang C, Yan L, Zhang LM (2011) Star-shaped polymers consisting of a β-cyclodextrin core and poly(amidoamine) dendron arms: binding and release studies with methotrexate and siRNA. J Mater Chem 21:5273–5281CrossRef
go back to reference Flavio C (2016) Martina, Fiocch, Angelina, Sacchi, Alessandro, Gori, Anna, Gasparri, NGR-tagged nano-gold: a new CD13-selective carrier for cytokine delivery to tumors. Nano Res 9:1393CrossRef Flavio C (2016) Martina, Fiocch, Angelina, Sacchi, Alessandro, Gori, Anna, Gasparri, NGR-tagged nano-gold: a new CD13-selective carrier for cytokine delivery to tumors. Nano Res 9:1393CrossRef
go back to reference Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ, Liang WQ, Gao JQ (2012) Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Controlled Release 163:136–144CrossRef Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ, Liang WQ, Gao JQ (2012) Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Controlled Release 163:136–144CrossRef
go back to reference Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. JNCI J Natl Cancer Inst 88:1442–1455CrossRefPubMed Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. JNCI J Natl Cancer Inst 88:1442–1455CrossRefPubMed
go back to reference Hyung W, Ko H, Park J, Lim E, Park SB, Park YJ, Yoon HG, Suh JS, Haam S, Huh YM (2008) Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol Bioeng 99:442CrossRefPubMed Hyung W, Ko H, Park J, Lim E, Park SB, Park YJ, Yoon HG, Suh JS, Haam S, Huh YM (2008) Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol Bioeng 99:442CrossRefPubMed
go back to reference Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 19:387–400CrossRefPubMed Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 19:387–400CrossRefPubMed
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Ca A Cancer J Clin 61:69CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Ca A Cancer J Clin 61:69CrossRef
go back to reference Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K (2010) Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 383:293–296CrossRefPubMed Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K (2010) Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 383:293–296CrossRefPubMed
go back to reference Kokkinakis DM, Brickner AG, Kirkwood JM, Liu X, Goldwasser JE, Kastrama A, Sander C, Bocangel D, Chada S (2006) Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res 4:575–589CrossRefPubMed Kokkinakis DM, Brickner AG, Kirkwood JM, Liu X, Goldwasser JE, Kastrama A, Sander C, Bocangel D, Chada S (2006) Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res 4:575–589CrossRefPubMed
go back to reference Kuo WY, Hwu L, Wu CY, Lee JS, Chang CW, Liu RS (2017) STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer Kuo WY, Hwu L, Wu CY, Lee JS, Chang CW, Liu RS (2017) STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer
go back to reference Li Volsi A, Jimenez de Aberasturi D, Henriksen-Lacey M, Giammona G, Licciardi M, Liz-Marzan LM (2016) Inulin coated plasmonic gold nanoparticles as a tumor-selective tool for cancer therapy. J Mater Chem B Mater Biol Med 4:1150–1155CrossRefPubMedPubMedCentral Li Volsi A, Jimenez de Aberasturi D, Henriksen-Lacey M, Giammona G, Licciardi M, Liz-Marzan LM (2016) Inulin coated plasmonic gold nanoparticles as a tumor-selective tool for cancer therapy. J Mater Chem B Mater Biol Med 4:1150–1155CrossRefPubMedPubMedCentral
go back to reference Liang X, Li X, Chang J, Duan Y, Li Z (2013) Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer-targeted gene delivery. Langmuir 29:8683–8693 Liang X, Li X, Chang J, Duan Y, Li Z (2013) Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer-targeted gene delivery. Langmuir 29:8683–8693
go back to reference Ma N, Wu FG, Zhang X, Jiang YW, Jia HR, Wang HY, Li YH, Liu P, Gu N, Chen Z, Shape-dependent radiosensitization effect of gold nanostructures in cancer radiotherapy: comparison of gold nanoparticles, Nanospikes Ma N, Wu FG, Zhang X, Jiang YW, Jia HR, Wang HY, Li YH, Liu P, Gu N, Chen Z, Shape-dependent radiosensitization effect of gold nanostructures in cancer radiotherapy: comparison of gold nanoparticles, Nanospikes
go back to reference Machover D, Zittoun J, Saffroy R, Broët P, Giraudier S, Magnaldo T, Goldschmidt E, Debuire B, Orrico M, Tan Y (2002) Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis. Can Res 62:4685–4689 Machover D, Zittoun J, Saffroy R, Broët P, Giraudier S, Magnaldo T, Goldschmidt E, Debuire B, Orrico M, Tan Y (2002) Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis. Can Res 62:4685–4689
go back to reference Miki K, Alrefaie W, Xu M, Jiang P, Tan Y, Bouvet M, Zhao M, Gupta A, Chishima T, Shimada H (2000a) Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Can Res 60:2696–2702 Miki K, Alrefaie W, Xu M, Jiang P, Tan Y, Bouvet M, Zhao M, Gupta A, Chishima T, Shimada H (2000a) Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Can Res 60:2696–2702
go back to reference Miki K, Xu M, An Z, Wang X, Yang M, Al-Refaie W, Sun X, Baranov E, Tan Y, Chishima T (2000b) Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model. Cancer Gene Ther 7:332–338CrossRefPubMed Miki K, Xu M, An Z, Wang X, Yang M, Al-Refaie W, Sun X, Baranov E, Tan Y, Chishima T (2000b) Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model. Cancer Gene Ther 7:332–338CrossRefPubMed
go back to reference Naor D (2016) Editorial: interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front Immunol 7:39CrossRefPubMedPubMedCentral Naor D (2016) Editorial: interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front Immunol 7:39CrossRefPubMedPubMedCentral
go back to reference Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK (2010) Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Controlled Rel Off J Control Rel Soc 141:2–12CrossRef Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK (2010) Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Controlled Rel Off J Control Rel Soc 141:2–12CrossRef
go back to reference Pissuwan D, Niidome T, Cortie MB (2011) The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 149:65–71CrossRefPubMed Pissuwan D, Niidome T, Cortie MB (2011) The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 149:65–71CrossRefPubMed
go back to reference Platt VM, Jr SF (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5:474–486CrossRefPubMedPubMedCentral Platt VM, Jr SF (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5:474–486CrossRefPubMedPubMedCentral
go back to reference Rocco A, Compare D, Nardone G (2012) Cancer stem cell hypothesis and gastric carcinogenesis: experimental evidence and unsolved questions. World J Gastrointestinal Oncol 4:54–59CrossRef Rocco A, Compare D, Nardone G (2012) Cancer stem cell hypothesis and gastric carcinogenesis: experimental evidence and unsolved questions. World J Gastrointestinal Oncol 4:54–59CrossRef
go back to reference Shah MA, Kelsen DP (2010) Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Comprehensive Cancer Netw JNCCN 8:437–447CrossRef Shah MA, Kelsen DP (2010) Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Comprehensive Cancer Netw JNCCN 8:437–447CrossRef
go back to reference Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, Shen M, Guo R, Tomás H, Shi X (2012a) Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 33:3025–3035CrossRefPubMed Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, Shen M, Guo R, Tomás H, Shi X (2012a) Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 33:3025–3035CrossRefPubMed
go back to reference Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, Shen M, Guo R, Tomas H, Shi X (2012b) Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 33:3025–3035CrossRefPubMed Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, Shen M, Guo R, Tomas H, Shi X (2012b) Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 33:3025–3035CrossRefPubMed
go back to reference Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, § TCW (2009) Identification of gastric cancer stem cells using the cell surface marker CD44 † ‡. Stem Cells 27:1006–1020CrossRefPubMedPubMedCentral Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, § TCW (2009) Identification of gastric cancer stem cells using the cell surface marker CD44 † ‡. Stem Cells 27:1006–1020CrossRefPubMedPubMedCentral
go back to reference Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z (1999) Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5:2157–2163PubMed Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z (1999) Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5:2157–2163PubMed
go back to reference Uthaman S, Zheng S, Han J, Choi YJ, Cho S, Nguyen VD, Park JO, Park SH, Min JJ, Park S (2015) Preparation of engineered salmonella typhimurium-driven hyaluronic-acid-based microbeads with both chemotactic and biological targeting towards breast cancer cells for enhanced anticancer therapy. Adv Healthcare Mater 5:288–295CrossRef Uthaman S, Zheng S, Han J, Choi YJ, Cho S, Nguyen VD, Park JO, Park SH, Min JJ, Park S (2015) Preparation of engineered salmonella typhimurium-driven hyaluronic-acid-based microbeads with both chemotactic and biological targeting towards breast cancer cells for enhanced anticancer therapy. Adv Healthcare Mater 5:288–295CrossRef
go back to reference Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Can Res 54:6228 Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Can Res 54:6228
go back to reference Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Zhang M (2011) Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomed 6:1747 Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Zhang M (2011) Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomed 6:1747
go back to reference Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A, Xu S, Røe OD, Wang M, Zhang R (2014) JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells. Cell Death Dis 5:e1551CrossRefPubMedPubMedCentral Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A, Xu S, Røe OD, Wang M, Zhang R (2014) JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells. Cell Death Dis 5:e1551CrossRefPubMedPubMedCentral
go back to reference Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C (2004) PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Can Res 64:6673–6678CrossRef Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C (2004) PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Can Res 64:6673–6678CrossRef
go back to reference Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS (2014) CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res 20:3974CrossRefPubMedPubMedCentral Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS (2014) CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res 20:3974CrossRefPubMedPubMedCentral
go back to reference Yu H, Nie Y, Dohmen C, Li Y, Wagner E (2011) Epidermal growth factor-PEG functionalized PAMAM-pentaethylenehexamine dendron for targeted gene delivery produced by click chemistry. Biomacromol 12:2039–2047CrossRef Yu H, Nie Y, Dohmen C, Li Y, Wagner E (2011) Epidermal growth factor-PEG functionalized PAMAM-pentaethylenehexamine dendron for targeted gene delivery produced by click chemistry. Biomacromol 12:2039–2047CrossRef
go back to reference Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C (2013) Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 5:178–183CrossRefPubMed Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C (2013) Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 5:178–183CrossRefPubMed
Metadata
Title
Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells
Authors
Yi-Fan Li
Hou-Ting Zhang
Lin Xin
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2678-5

Other articles of this Issue 8/2018

Journal of Cancer Research and Clinical Oncology 8/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.